Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Cantor Fitzgerald has reaffirmed its Overweight recommendation for Vaxcyte, a vaccine development company currently valued at $7.05 billion. Despite a nearly 48% rise in stock price over six months, the company remains unprofitable with a diluted EPS of -$4.84 over the past year. The firm’s positive stance is driven by ongoing clinical trials progr…
Goldman Sachs has raised the price target for CEMEX's stock to $13.00 from $11.50, reinforcing its Buy stance ahead of the cement manufacturer’s upcoming Q4 2025 earnings report. This revision aligns closely with InvestingPro’s Fair Value analysis, suggesting the stock remains slightly undervalued despite recent gains near its 52-week high. The fir…
RBC Capital has confirmed its Sector Perform rating and $21.00 target price for Kenvue Inc as the company approaches a February earnings report. While the firm anticipates a modest quarter due to market pressures, the valuation reflects potential benefits from prior year comparisons and recent corporate developments, including Kimberly-Clark's acqu…
Goldman Sachs has improved its recommendations on two key European real estate companies, anticipating better performance ahead of their 2025 financial year results. The upgrades reflect an optimized valuation perspective and evolving macroeconomic conditions, with prospects pointing toward stable earnings and net asset growth for the sector.
Fortinet's stock experienced a notable increase after TD Cowen upgraded its rating from Hold to Buy, maintaining a $100 price target. Analyst Shaul Eyal emphasized stable fiscal year 2026 outlook based on recent checks, and highlighted artificial intelligence as a complement rather than a competitor to security software. Despite some concerns regar…
UBS retains a neutral outlook on UK equities, citing that the FTSE 100's impressive 22% return last year was largely concentrated among a small number of firms. The brokerage indicates that future stock market progress will rely principally on earnings growth rather than further multiple expansion amid persistent high bond yields. UBS forecasts mod…
Stephens has increased its price target for Business First Bancshares to $35, up from $34, reflecting the company’s strong fourth-quarter results for 2025. The investment firm highlighted the bank's impressive fee income, solid loan growth, and favorable balance sheet repricing as key factors fueling a 10% beat on consensus pre-provision net revenu…
Stephens has increased its price target for Opendoor Technologies to $37 from $35 and kept an Overweight rating, citing anticipated earnings in line with estimates and promising growth prospects. The company’s transition to a new ticker symbol and upcoming analyst day contribute to positive investor sentiment. Meanwhile, Openlane's recent strategic…
Piper Sandler has reaffirmed its Overweight rating and set a $450 price target for Praxis Precision Medicines, citing promising developments in the company's pipeline for essential tremor and developmental epileptic encephalopathies. Despite recent stock surges pushing valuations near their peak, analyst confidence remains strong due to upcoming Ne…
Stephens has increased the price target for United Bankshares Inc. (NASDAQ: UBSI) from $40.00 to $44.00, maintaining an Equal Weight rating. This move follows the company's stronger-than-expected earnings per share of $0.92, surpassing consensus estimates, and highlights solid operational performance including improved asset quality and growth in n…
Scotiabank has elevated its price forecast for Kinder Morgan stock to $30, reflecting robust operational achievements and favorable regulatory progress on key projects. Despite the price adjustment, the stock trades near its upper historical bounds, with momentum indicators suggesting a potential overbought status.
Stephens has increased its price target for Columbia Banking System to $37, signaling approximately 25% upside from its recent trading level. This adjustment follows the bank's strong fourth-quarter earnings which exceeded expectations, alongside promising revenue and net interest income performance. Multiple analysts have similarly raised their pr…
Abbott Laboratories experienced a significant stock price decline following Piper Sandler's decision to reduce its price target from $150 to $135 in response to weaker-than-expected fourth-quarter revenue, primarily driven by challenges in its Nutrition segment. Despite the revenue miss, the company met adjusted earnings per share estimates and sho…
Piper Sandler has adjusted its price target for OFG Bancorp to $43, down from $45, while retaining a Neutral rating. The revision follows a notable share price drop after the company's recent earnings announcement, which analysts attribute to market misinterpretation of seasonal factors in its auto loan segment. The firm also lowered its profit for…
RBC Capital has decreased its price target for CSX Corporation to $39 from $40, noting the company’s recent financial results are broadly in line with expectations despite a sluggish freight market. The railroad reported modest revenue declines and adjusted guidance reflecting low single-digit growth and margin improvements. Analysts remain positiv…
Piper Sandler has raised its price target for Intuitive Surgical to $620, reflecting confidence in the company's solid margin expansion and revenue growth. The surgical robotics firm recently reported better-than-expected fourth-quarter financial results, reinforcing its strong position in the medtech sector. While the stock trades above its fair v…
Bausch Health's stock experienced an 8% decline after the pharmaceutical firm disclosed that its Phase 3 trials investigating amorphous-rifaximin SSD for preventing initial hepatic encephalopathy episodes in adults with liver cirrhosis did not achieve the primary efficacy goals. Despite the trials demonstrating the drug's safety and tolerability, t…
Piper Sandler has increased its price target on Chipotle Mexican Grill to $47 from $44, citing potential growth momentum in 2026. The firm maintains an Overweight rating, noting that the stock currently trades at a high valuation relative to growth expectations. This revision comes as the market anticipates Chipotle's upcoming earnings report and r…
H.C. Wainwright has upheld its Buy rating on Silence Therapeutics shares, assigning a price target of $75 following discussions with company executives. The firm emphasizes the promising progress of the lead asset divesiran for polycythemia vera, supported by a fully enrolled Phase 2 trial, as well as the broader pipeline advancing toward high-valu…
Ahead of Deckers Outdoor's fiscal third-quarter earnings release, Piper Sandler has upheld its Underweight rating with a price target well below current fair value assessments. While Deckers shows strong revenue growth and robust financial health, apprehensions persist about the long-term prospects of its HOKA brand within the U.S. market and poten…
H.C. Wainwright has confirmed a Buy rating and a $50 price target for Aligos Therapeutics following a recent update on its Phase 2 B-SUPREME clinical trial evaluating pevifoscorvir sodium for chronic hepatitis B. The trial's progress and the company’s strategic initiatives in metabolic liver disease have strengthened investor confidence, while the …
Piper Sandler has reaffirmed an Overweight recommendation for Align Technology, underpinned by a 3.3% year-over-year rise in U.S. clear aligner volumes during December and the likelihood of upward adjustments in earnings forecasts. The firm's target price of $200 signals an 18% gain from current stock levels, with valuation metrics indicating poten…
H.C. Wainwright reaffirmed its Buy stance on Invivyd Inc., maintaining a $10 price target, following a recent dialogue with the company’s leadership. This valuation implies substantial upside relative to the current stock price, reflecting confidence in Invivyd’s forthcoming Phase 3 results for VYD2311 and growth from the PEMGARDA franchise. The co…
In 2025, TikTok, a ByteDance-owned short-video platform, continued to hold its position as the second-most-downloaded app in the United States, overshadowing ongoing political challenges and regulatory scrutiny related to its Chinese ownership. Other apps linked to Chinese companies, including ByteDance’s CapCut and e-commerce site Temu, also maint…
UBS Group AG, the world's largest wealth manager, is exploring the introduction of cryptocurrency investment options for select private banking clients, starting in Switzerland. The bank is in the process of selecting partners to facilitate trading in digital assets such as Bitcoin and Ether, with possible future expansion to Asia-Pacific and the U…
